Sylvain Garciaz - Hematol Dept, Inst Paoli Calmettes

基本信息

Career Trajectory

Bio

I am a physician-scientist specialized in hematology. I did my medical school at Marseille University in France and my PhD in the Marseille Cancer Research Center focusing on AML resistance to therapeutics. I went in The Mark Dawson' s Lab at PeterMac Callum Cancer Centre in Melbourne in 2019 for a post doctoral fellowship where I had the opportunity to study the effect of a small molecule inducing alternative cell death in AML. My scientific work focus on resistance to BH3 mimetics in acute myeloid leukaemia and new therapeutics. I am in charge of the early phase clinical trials in AML at Paoli-Calmettes Institute in Marseille.

Research Interests

Papers共 133 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Venetoclax Resistance in Acute Myeloid Leukemia

Sylvain Garciaz,Marie-Anne Hospital,Yves Collette,Norbert Vey

Cancersno. 6 (2024)

Cited2Views0WOSBibtex

Preliminary Results of a Phase 1, First-in-human Study of INA03, an Anti-Cd71 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Sylvain Garciaz,Pierre Bories,Jean-Marie Boher,Marie Anne Hospital,Christian Recher,Colombe Saillard,Yosr Hicheri, Renato Monteiro,Olivier Hermine,Pierre Launay,Norbert Vey

BLOOD (2024): 1496-1497

Cited0Views0Bibtex

Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Pierre-Yves Dumas,Sarah Bertoli,Clemence Santana,Mael Heiblig,Thibaut Leguay,Suzanne Tavitian,Eric Delabesse,Emilie Klein,Emmanuelle Tavernier,Martin Carre,Gaspar Aspas Requena,Anne Banos,Norbert Vey,Arnaud Pigneux,Christian Recher,Sylvain Garciaz

BLOOD (2024): 4275-4276

Cited0Views0Bibtex

Long-term Survival of NPM1 AML Treated with Intensive Chemotherapy with Extensive Molecular Data Available

Sylvain Garciaz,Guillaume Berton,Marie-Anne Hospital,Arnaud Guille,Jose Adelaide,Colombe Saillard,Yosr Hicheri,Marie-Joelle Mozziconacci,Estelle Duprez,Christian Recher,Anne-Sophie Alary,Daniel Birnbaum,Norbert Vey

LEUKEMIA & LYMPHOMAno. 5 (2024): 700-703

Cited0Views0WOSBibtex

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Christian Recher,Jenny O'Nions,Ibrahim Aldoss,Ana Alfonso Pierola, Alicia Allred,Juan Manuel Alonso-Dominguez,Laura Barreyro,Pierre Bories,Martin Curtis,Nikki Daskalakis,Matteo Giovanni Della Porta,Hartmut Döhner, Amber D'Souza, James P. Dugan,Jordi Esteve Reyner, Matthew Exum,Amir T. Fathi,Pasquale L. Fedele,Lucille Ferrante, Stan Gaj,Sylvain Garciaz,Ana Garrido,Sara Garrido Paniagua,Christina Guttke,Emmanuel Gyan,Brett Hiebert,Elias Jabbour, Madlen Jentzsch,Hagop M. Kantarjian,Marina Konopleva,Jan Krönke,Min Chul Kwon, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris,Giovanni Martinelli,Daniel Morillo Giles, Joseph Murphy,Kathryn Packman,Cristina Papayannidis,Ulrike Philippar,Uwe Platzbecker,Sravanti Rangaraju, Christoph Röllig,Olga Salamero,Madhu Sanga,Tim Sauer,Emma Searle, Natalia Tovar, Trevor Tucker,Nicolas Vallet, Lachlin Vaughan, Gala Vega,Paresh Vyas,Andrew Wei

Bloodno. Supplement 1 (2024): 215-215

Cited0Views0Bibtex

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed by Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Bloodno. Supplement 1 (2024): 1508-1508

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn